{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:26:39Z","timestamp":1784618799931,"version":"3.55.0"},"reference-count":5,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2016,5,3]]},"abstract":"<jats:p>Inverse psoriasis is characterised by the involvement of flexural skin folds. This form of psoriasis has distinct clinical and therapeutic features. This report refers to the case of a 48-year-old Caucasian man who was observed in our department, with a clinically and biopsy proven diagnosis of inverse psoriasis. For 2\u2005years, the patient was treated with different combinations of corticosteroids, vitamin D analogues and methotrexate, with no satisfactory response. Given the lack of a clinical response and comorbidities, latent tuberculosis was excluded, and we started treatment with ustekinumab. We chose this biological agent because the patient was a long-distance truck driver and refused the possibility of autoinjections. The patient underwent three ustekinumab injections, which resulted in significant improvement of pruritus, erythaematous lesions and quality of life.<\/jats:p>","DOI":"10.1136\/bcr-2016-215019","type":"journal-article","created":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T14:52:27Z","timestamp":1464101547000},"page":"bcr2016215019","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Inverse psoriasis treated with ustekinumab"],"prefix":"10.1136","volume":"2016","author":[{"given":"Manuel Ant\u00f3nio","family":"Campos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Baptista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Isabel","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,5,24]]},"reference":[{"key":"2025042703272159000_2016.may24_1.bcr2016215019.1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2002.01462.x"},{"key":"2025042703272159000_2016.may24_1.bcr2016215019.2","first-page":"176","article-title":"Clinical analysis of 48 cases of inverse psoriasis: a hospital-based study","volume":"15","author":"Wang","year":"2005","journal-title":"Eur J Dermatol"},{"key":"2025042703272159000_2016.may24_1.bcr2016215019.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2015.04.007"},{"key":"2025042703272159000_2016.may24_1.bcr2016215019.4","unstructured":"Stelara (ustekinumab) [prescribing information]. Beerse, Belgium: Janssen Biotech, 2009."},{"key":"2025042703272159000_2016.may24_1.bcr2016215019.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2016-215019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T10:27:29Z","timestamp":1745749649000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2016-215019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,24]]},"references-count":5,"alternative-id":["10.1136\/bcr-2016-215019"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2016-215019","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,24]]}}}